Citius Pharmaceuticals, Inc. (CTXR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Citius Pharmaceuticals, Inc. in 2026. The next earnings report is expected on December 17, 2026.
Citius Pharmaceuticals beat consensus on EPS but missed on revenue, with EPS of $-0.34 versus an estimate of $-0.36 and revenue of $1.49 million falling 72.6% short of the $5.46 million estimate. In the prior report, both EPS and revenue missed expectations.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
